Grail Inc (GRAL)

$63.44 -0.98 (-1.52%)
Market Cap 2.76B
Revenue (ttm) 147.17M
Net Income (ttm) -408.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -277.47%
Debt to Equity Ratio 0.00
Volume 518,600
Avg Vol 682,962
Day's Range N/A - N/A
Shares Out 42.92M
Stochastic %K 12%
Beta 3.22
Analysts Sell
Price Target $70.12

Company Profile

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therap...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 833 694 2553
Website: grail.com
Address:
1525 O’Brien Drive, Menlo Park, United States
DannyGh8st
DannyGh8st Jul. 26 at 7:38 PM
$GRAL Has a Potential growth from successful clinical validation and adoption..
0 · Reply
EthanH199
EthanH199 Jul. 25 at 12:35 AM
$GRAL
0 · Reply
11thestate
11thestate Jul. 16 at 4:24 PM
If you're a $GRAL investor, there's a case you should know about. We have all the details, including how to join the case and stay informed about any potential recovery. Check it out: https://11th.com/cases/grail-investor-suit
0 · Reply
gobio
gobio Jul. 16 at 1:36 PM
$GRAL GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a collaboration with Priority Health, a nationally recognized nonprofit health plan and the third largest provider-sponsored health plan in the nation, to make GRAIL's Galleri® multi-cancer early detection (MCED) test available to Priority Health's self-insured employer groups. Priority Health launched coverage for Galleri in its Thrive and Thrive Plus Medicare Advantage plans in 2025 and is expanding on its partnership with GRAIL to become the first Michigan health plan to enable its employer groups to easily add the Galleri test to their existing cancer screening coverage.
0 · Reply
juracquis13
juracquis13 Jul. 13 at 11:48 AM
https://stocktwits.com/news-articles/markets/equity/why-is-gral-stock-down-today-analysts-lower-targets-after-uk-trial-setback-selloff-overdone/cZRN5uHR4x9 $GRAL I wouldn't pay $10K for a cybertruck.
0 · Reply
BillionerOfKing
BillionerOfKing Jul. 9 at 8:49 PM
$GRAL Current Stock Price: $75.84 Contracts to trade: $75.0 GRAL Jul 17 2026 Call Entry: $1.75 Exit: $2.90 ROI: 66% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
JFDI
JFDI Jul. 9 at 1:41 PM
even the holy $GRAL curling up off the beat down
0 · Reply
BinaryLogic
BinaryLogic Jun. 23 at 1:03 AM
$GRAL just made news on NPR for its Galleri test pending FDA approval at the close of the year. GRAL has a market cap of $2.7B. While the Galleri test is pioneering liquid biopsy technology, it is relatively expensive $1000, long-lead and limited to specialized technical labs. Contrast that with $VNRX CaptureSeq which shows comparable specificity, but outstanding detection of Phs-1/2 cancers at a fraction of the cost using technology at nearly any/all hospitals worldwide. IP secured to 2044 and market cap of $12M, grossly Oversold and in discussions with all leading liquidity biopsy/diagnostic Companies globally on licensing agreements. https://www.npr.org/2026/06/21/nx-s1-5858691/blood-test-multi-cancer-early-detection-mced
1 · Reply
bonniewinter
bonniewinter Jun. 16 at 5:35 PM
$GRAL looks like Goldman Sachs $60PT has places a lid on the share price. Grails’s MCED test Galleri is being adopted well with private payors and Tricare. Revenue is exceeding expectations each quarter. All clinical trials including Pathfinder 2 and UK NHS trial have confirmed superior clincial validity which is the main basis for FDA approval. Regarding clinical utility, they showed a remarkable 20% improvement in delaying progression to Stage 4 cancers and have commenced the REACH trial with Medicare patients to confirm this finding from the UK trial. The Medical Oncology community and cancer patients are elated about early detection and early interventions for many cancers which still do not have any primary screening. Bill Gates & Jeff Bezos remain large shareholders of this industry disruptor technology, the first of its kind which will achieve FDA APPROVAL soon.
0 · Reply
Bazzzigar
Bazzzigar Jun. 9 at 5:40 PM
$GRAL moved to MANE
0 · Reply
Latest News on GRAL
GRAIL to Announce Second Quarter 2026 Financial Results

Jul 29, 2026, 4:01 PM EDT - 16 hours ago

GRAIL to Announce Second Quarter 2026 Financial Results

$GRAL Fraud Notification: GRAIL, Inc. Sued for Fraud Over Misrepresentations about its Trial Results – Investors Notified to Contact BFA Law

Jul 24, 2026, 6:36 AM EDT - 6 days ago

$GRAL Fraud Notification: GRAIL, Inc. Sued for Fraud Over Misrepresentations about its Trial Results – Investors Notified to Contact BFA Law

Grail’s Gallery cancer detection test adopted by Priority Health

2026-07-16T13:11:41.000Z - 13 days ago

Grail’s Gallery cancer detection test adopted by Priority Health

Priority Health Collaborates With GRAIL as the First Michigan Health Plan to Offer the Galleri® Multi-Cancer Early Detection Blood Test to Employer Plans

Jul 16, 2026, 9:00 AM EDT - 13 days ago

Priority Health Collaborates With GRAIL as the First Michigan Health Plan to Offer the Galleri® Multi-Cancer Early Detection Blood Test to Employer Plans

Grail price target raised to $88 from $69 at TD Cowen

2026-07-15T12:50:43.000Z - 14 days ago

Grail price target raised to $88 from $69 at TD Cowen

Grail price target raised to $65 from $58 at Mizuho

2026-07-15T11:32:38.000Z - 15 days ago

Grail price target raised to $65 from $58 at Mizuho

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 4, 2026 in Grail, Inc. Lawsuit - GRAL

Jul 14, 2026, 9:48 AM EDT - 15 days ago

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 4, 2026 in Grail, Inc. Lawsuit - GRAL

$GRAL Fraud Notification: GRAIL, Inc. Sued for Securities Fraud After Trial Results Spark a 50% Stock Drop – Investors Notified to Contact BFA Law by August 4

Jul 6, 2026, 6:48 AM EDT - 24 days ago

$GRAL Fraud Notification: GRAIL, Inc. Sued for Securities Fraud After Trial Results Spark a 50% Stock Drop – Investors Notified to Contact BFA Law by August 4

GRAIL, Inc. (GRAL) Securities Fraud: Contact Berger Montague to Discuss Your Rights

Jul 2, 2026, 9:37 AM EDT - 27 days ago

GRAIL, Inc. (GRAL) Securities Fraud: Contact Berger Montague to Discuss Your Rights

GRAL Investors Have Rights – If You Lost Money Investing in Grail, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Jul 1, 2026, 6:21 PM EDT - 4 weeks ago

GRAL Investors Have Rights – If You Lost Money Investing in Grail, Inc. Contact Robbins LLP for Information About Recovering Your Losses

GRAIL Completes $110 Million Equity Financing With Samsung Entities

Jun 25, 2026, 9:00 AM EDT - 4 weeks ago

GRAIL Completes $110 Million Equity Financing With Samsung Entities

GRAIL Transcript: AGM 2026

Jun 18, 2026, 4:00 PM EDT - 5 weeks ago

GRAIL Transcript: AGM 2026

GRAL Breaking News: GRAIL, Inc. Sued for Securities Fraud after Trial Results Lead to 50% Stock Drop – Investors Notified to Contact BFA Law

Jun 12, 2026, 4:07 PM EDT - 6 weeks ago

GRAL Breaking News: GRAIL, Inc. Sued for Securities Fraud after Trial Results Lead to 50% Stock Drop – Investors Notified to Contact BFA Law

GRAIL, INC. (GRAL) INVESTOR ALERT Investors With Large Losses in GRAIL, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Jun 10, 2026, 9:47 AM EDT - 7 weeks ago

GRAIL, INC. (GRAL) INVESTOR ALERT Investors With Large Losses in GRAIL, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

GRAIL Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 11:20 AM EDT - 7 weeks ago

GRAIL Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Grail initiated with a Neutral at Goldman Sachs

2026-06-05T08:40:29.000Z - 7 weeks ago

Grail initiated with a Neutral at Goldman Sachs

GRAIL Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 7:35 AM EDT - 2 months ago

GRAIL Transcript: Jefferies Global Healthcare Conference 2026

Grail assumed with a Peer Perform at Wolfe Research

2026-06-01T20:52:46.000Z - 2 months ago

Grail assumed with a Peer Perform at Wolfe Research

Grail falls -15.6%

2026-06-01T16:35:00.000Z - 2 months ago

Grail falls -15.6%

Grail falls -18.4%

2026-06-01T16:10:37.000Z - 2 months ago

Grail falls -18.4%

GRAIL Transcript: Study result

May 31, 2026, 7:00 PM EDT - 2 months ago

GRAIL Transcript: Study result

GRAIL Press release: Study result

May 31, 2026, 7:00 PM EDT - 2 months ago

GRAIL Press release: Study result

GRAIL Slides: Study result

May 31, 2026, 7:00 PM EDT - 2 months ago

GRAIL Slides: Study result

Grail presents ‘positive’ performance, safety results from Pathfinder 2 study

2026-05-31T21:43:31.000Z - 2 months ago

Grail presents ‘positive’ performance, safety results from Pathfinder 2 study

Grail reports results from NHS-Galleri trial in presentation at ASCO meeting

2026-05-31T21:36:48.000Z - 2 months ago

Grail reports results from NHS-Galleri trial in presentation at ASCO meeting

GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting

May 31, 2026, 8:00 AM EDT - 2 months ago

GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting

GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting

May 30, 2026, 8:00 AM EDT - 2 months ago

GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting

GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

May 27, 2026, 4:01 PM EDT - 2 months ago

GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GRAIL to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 26, 2026, 4:01 PM EDT - 2 months ago

GRAIL to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

GRAIL to Present at the 2026 Jefferies Global Healthcare Conference

May 21, 2026, 4:01 PM EDT - 2 months ago

GRAIL to Present at the 2026 Jefferies Global Healthcare Conference

GRAIL Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 11:40 AM EDT - 2 months ago

GRAIL Transcript: Bank of America Global Healthcare Conference 2026

Grail price target lowered to $70 from $82 at Baird

2026-05-07T09:18:38.000Z - 3 months ago

Grail price target lowered to $70 from $82 at Baird

Grail price target raised to $56 from $54 at Piper Sandler

2026-05-07T07:52:29.000Z - 3 months ago

Grail price target raised to $56 from $54 at Piper Sandler

Grail price target raised to $69 from $65 at TD Cowen

2026-05-07T05:21:56.000Z - 3 months ago

Grail price target raised to $69 from $65 at TD Cowen

Zaya Younan Unveils the Scientific Holy Grail of Cigar Smoking

May 6, 2026, 10:00 AM EDT - 3 months ago

Zaya Younan Unveils the Scientific Holy Grail of Cigar Smoking

Grail reports Q1 EPS ($2.29), consensus ($1.96)

2026-05-05T20:33:50.000Z - 3 months ago

Grail reports Q1 EPS ($2.29), consensus ($1.96)

GRAIL Earnings Call Transcript: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

GRAIL Earnings Call Transcript: Q1 2026

GRAIL Earnings release: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

GRAIL Earnings release: Q1 2026

GRAIL Quarterly report: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

GRAIL Quarterly report: Q1 2026

GRAIL Reports First Quarter 2026 Financial Results

May 5, 2026, 4:01 PM EDT - 3 months ago

GRAIL Reports First Quarter 2026 Financial Results

GRAIL to Present at the BofA Securities 2026 Health Care Conference

Apr 30, 2026, 4:01 PM EDT - 3 months ago

GRAIL to Present at the BofA Securities 2026 Health Care Conference

GRAIL Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 3 months ago

GRAIL Proxy statement: Proxy filing

GRAIL Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 3 months ago

GRAIL Proxy statement: Proxy filing

GRAIL to Announce First Quarter 2026 Financial Results

Apr 22, 2026, 4:01 PM EDT - 3 months ago

GRAIL to Announce First Quarter 2026 Financial Results

GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at 2026 ASCO Annual Meeting

Apr 21, 2026, 4:53 PM EDT - 3 months ago

GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at 2026 ASCO Annual Meeting

Grail initiated with a Neutral at Mizuho

2026-04-10T09:55:12.000Z - 3 months ago

Grail initiated with a Neutral at Mizuho

Grail initiated with a Neutral at Piper Sandler

2026-04-10T08:45:11.000Z - 3 months ago

Grail initiated with a Neutral at Piper Sandler

Grail announces collaboration with Epic to bring Galleri test to EHR platforms

2026-04-07T20:05:13.000Z - 4 months ago

Grail announces collaboration with Epic to bring Galleri test to EHR platforms

GRAIL Announces Integration of the Galleri® Test into Epic Electronic Health Record Platform to Expand Access Nationwide

Apr 7, 2026, 4:01 PM EDT - 4 months ago

GRAIL Announces Integration of the Galleri® Test into Epic Electronic Health Record Platform to Expand Access Nationwide

Grail, Superpower partner to expand early cancer detection

2026-04-01T17:15:43.000Z - 4 months ago

Grail, Superpower partner to expand early cancer detection

Cancer Is Striking Earlier -- Superpower and GRAIL Are Partnering to Expand Early Detection

Apr 1, 2026, 1:09 PM EDT - 4 months ago

Cancer Is Striking Earlier -- Superpower and GRAIL Are Partnering to Expand Early Detection

Grail price target lowered to $75 from $130 at Guggenheim

2026-03-30T11:54:36.000Z - 4 months ago

Grail price target lowered to $75 from $130 at Guggenheim

Grail CEO Bob Ragusa to retire, Josh Ofman named successor

Mar 12, 2026, 6:13 PM EDT - 4 months ago

Grail CEO Bob Ragusa to retire, Josh Ofman named successor

GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor

Mar 12, 2026, 4:30 PM EDT - 4 months ago

GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor

Levi & Korskinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed

Mar 5, 2026, 9:00 AM EST - 5 months ago

Levi & Korskinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed

GRAIL Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 10:30 AM EST - 5 months ago

GRAIL Transcript: TD Cowen 46th Annual Health Care Conference

GRAIL to Present at the TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 4:02 PM EST - 5 months ago

GRAIL to Present at the TD Cowen 46th Annual Health Care Conference

'Holy Grail' Honus Wagner card sells for over $5M as family auctions it from grandfather's collection

Feb 23, 2026, 9:06 AM EST - 5 months ago

'Holy Grail' Honus Wagner card sells for over $5M as family auctions it from grandfather's collection

This once-hot cancer-detection company's stock got cut in half after a failed trial

Feb 20, 2026, 4:26 PM EST - 5 months ago

This once-hot cancer-detection company's stock got cut in half after a failed trial

Grail shares plunge after major cancer screening trial misses main goal

Feb 20, 2026, 8:35 AM EST - 5 months ago

Grail shares plunge after major cancer screening trial misses main goal

Grail Stock Plunges 50% After Earnings. But It's These Test Results That Are to Blame.

Feb 20, 2026, 4:06 AM EST - 5 months ago

Grail Stock Plunges 50% After Earnings. But It's These Test Results That Are to Blame.

Grail Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Feb 19, 2026, 9:27 PM EST - 5 months ago

Grail Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

GRAIL Earnings Call Transcript: Q4 2025

Feb 19, 2026, 5:00 PM EST - 5 months ago

GRAIL Earnings Call Transcript: Q4 2025

GRAIL Annual report: Q4 2025

Feb 19, 2026, 5:00 PM EST - 5 months ago

GRAIL Annual report: Q4 2025

GRAIL Earnings release: Q4 2025

Feb 19, 2026, 5:00 PM EST - 5 months ago

GRAIL Earnings release: Q4 2025

GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 19, 2026, 4:02 PM EST - 5 months ago

GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results

Landmark NHS-Galleri Trial Demonstrates a Substantial Reduction in Stage IV Cancer Diagnoses, Increased Stage I and II Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate

Feb 19, 2026, 4:01 PM EST - 5 months ago

Landmark NHS-Galleri Trial Demonstrates a Substantial Reduction in Stage IV Cancer Diagnoses, Increased Stage I and II Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate

GRAIL to Announce Fourth Quarter and Full Year 2025 Financial Results

Feb 16, 2026, 9:00 AM EST - 5 months ago

GRAIL to Announce Fourth Quarter and Full Year 2025 Financial Results

GRAIL Submits FDA Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test

Jan 29, 2026, 7:25 PM EST - 6 months ago

GRAIL Submits FDA Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test

A Study on Aging Unlocks Holy Grail of Sports Performance

Jan 26, 2026, 8:00 AM EST - 6 months ago

A Study on Aging Unlocks Holy Grail of Sports Performance

GRAIL Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 10:30 AM EST - 7 months ago

GRAIL Transcript: 44th Annual J.P. Morgan Healthcare Conference

GRAIL Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 10:30 AM EST - 7 months ago

GRAIL Slides: 44th Annual J.P. Morgan Healthcare Conference

GRAIL to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 15, 2025, 4:01 PM EST - 8 months ago

GRAIL to Present at the 44th Annual J.P. Morgan Healthcare Conference

GRAIL Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 3:00 PM EST - 8 months ago

GRAIL Transcript: Piper Sandler 37th Annual Healthcare Conference

Deutsche Bank may have just set a holy-grail goal for the S&P 500

Nov 24, 2025, 9:11 AM EST - 8 months ago

Deutsche Bank may have just set a holy-grail goal for the S&P 500

DB IVV SPXL SPY SSO UPRO VOO

DannyGh8st
DannyGh8st Jul. 26 at 7:38 PM
$GRAL Has a Potential growth from successful clinical validation and adoption..
0 · Reply
EthanH199
EthanH199 Jul. 25 at 12:35 AM
$GRAL
0 · Reply
11thestate
11thestate Jul. 16 at 4:24 PM
If you're a $GRAL investor, there's a case you should know about. We have all the details, including how to join the case and stay informed about any potential recovery. Check it out: https://11th.com/cases/grail-investor-suit
0 · Reply
gobio
gobio Jul. 16 at 1:36 PM
$GRAL GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a collaboration with Priority Health, a nationally recognized nonprofit health plan and the third largest provider-sponsored health plan in the nation, to make GRAIL's Galleri® multi-cancer early detection (MCED) test available to Priority Health's self-insured employer groups. Priority Health launched coverage for Galleri in its Thrive and Thrive Plus Medicare Advantage plans in 2025 and is expanding on its partnership with GRAIL to become the first Michigan health plan to enable its employer groups to easily add the Galleri test to their existing cancer screening coverage.
0 · Reply
juracquis13
juracquis13 Jul. 13 at 11:48 AM
https://stocktwits.com/news-articles/markets/equity/why-is-gral-stock-down-today-analysts-lower-targets-after-uk-trial-setback-selloff-overdone/cZRN5uHR4x9 $GRAL I wouldn't pay $10K for a cybertruck.
0 · Reply
BillionerOfKing
BillionerOfKing Jul. 9 at 8:49 PM
$GRAL Current Stock Price: $75.84 Contracts to trade: $75.0 GRAL Jul 17 2026 Call Entry: $1.75 Exit: $2.90 ROI: 66% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
JFDI
JFDI Jul. 9 at 1:41 PM
even the holy $GRAL curling up off the beat down
0 · Reply
BinaryLogic
BinaryLogic Jun. 23 at 1:03 AM
$GRAL just made news on NPR for its Galleri test pending FDA approval at the close of the year. GRAL has a market cap of $2.7B. While the Galleri test is pioneering liquid biopsy technology, it is relatively expensive $1000, long-lead and limited to specialized technical labs. Contrast that with $VNRX CaptureSeq which shows comparable specificity, but outstanding detection of Phs-1/2 cancers at a fraction of the cost using technology at nearly any/all hospitals worldwide. IP secured to 2044 and market cap of $12M, grossly Oversold and in discussions with all leading liquidity biopsy/diagnostic Companies globally on licensing agreements. https://www.npr.org/2026/06/21/nx-s1-5858691/blood-test-multi-cancer-early-detection-mced
1 · Reply
bonniewinter
bonniewinter Jun. 16 at 5:35 PM
$GRAL looks like Goldman Sachs $60PT has places a lid on the share price. Grails’s MCED test Galleri is being adopted well with private payors and Tricare. Revenue is exceeding expectations each quarter. All clinical trials including Pathfinder 2 and UK NHS trial have confirmed superior clincial validity which is the main basis for FDA approval. Regarding clinical utility, they showed a remarkable 20% improvement in delaying progression to Stage 4 cancers and have commenced the REACH trial with Medicare patients to confirm this finding from the UK trial. The Medical Oncology community and cancer patients are elated about early detection and early interventions for many cancers which still do not have any primary screening. Bill Gates & Jeff Bezos remain large shareholders of this industry disruptor technology, the first of its kind which will achieve FDA APPROVAL soon.
0 · Reply
Bazzzigar
Bazzzigar Jun. 9 at 5:40 PM
$GRAL moved to MANE
0 · Reply
TheUnmaker
TheUnmaker Jun. 9 at 11:47 AM
$TNXP $GRAL $CCCC $QSI
0 · Reply
ripster47
ripster47 Jun. 5 at 3:12 PM
$GRAL | Goldman Sachs Starts GRAIL, Inc. PT to $60 on Regulatory Milestones Goldman Sachs initiates coverage as FDA approval, CMS coverage, and MCED adoption remain key growth determinants 🔹 Follow @tenet_research for more analyst insights on other tickers.
0 · Reply
LewisDaKat
LewisDaKat Jun. 5 at 10:30 AM
$GRAL GRAL Price Target Alert: $60.00. Issued by Goldman Sachs https://marketwirenews.com/stock/gral/news/gral-price-target-alert-60-00-issued-by-goldman-sach-7221385765324160.html?utm_source=stocktwits
0 · Reply
LewisDaKat
LewisDaKat Jun. 5 at 10:00 AM
$GRAL Neutral Recommendation Issued On GRAL By Goldman Sachs https://marketwirenews.com/stock/gral/news/neutral-recommendation-issued-on-gral-by-goldman-sac-6688585928039035.html?utm_source=stocktwits
0 · Reply
gobio
gobio Jun. 5 at 12:14 AM
$GRAL https://www.statnews.com/2026/06/04/grail-multi-cancer-early-detection-test-trial-results/?utm_campaign=daily_recap&utm_medium=email&_hsenc=p2ANqtz-9ialr9z14UWDBeQ8mfefa1-B9rldpk8RJlOBPw4bFeO1wzj9_XIlVsit_cYS7grXgyiESn2M_IvnEBocosqAh9eq4knw&_hsmi=422308760&utm_content=422308760&utm_source=hs_email
0 · Reply
LewisDaKat
LewisDaKat Jun. 4 at 8:00 PM
$GRAL Why Grail Stock Popped Today https://marketwirenews.com/stock/gral/news/why-grail-stock-popped-today-4936013861703078.html?utm_source=stocktwits
0 · Reply
LewisDaKat
LewisDaKat Jun. 4 at 7:30 PM
$GRAL Is Grail Stock a Bad-News Buy After Its Recent Pullback? https://marketwirenews.com/stock/gral/news/is-grail-stock-a-bad-news-buy-after-its-recent-pullb-8995358004223520.html?utm_source=stocktwits
0 · Reply
CapitalMonk
CapitalMonk Jun. 4 at 3:13 PM
$GRAL Price: $68.09 (+11.39%) Trend: Bearish Market Bias (7D): Bearish Bias 📉 Expected Range: ±4.83% RSI: 57.9 | Momentum: Moderate Volume: -48.0% vs avg Volatility: 4.76% Support: $54.52 | Resistance: $79.50 Data and analytics sourced from Given Analytics educational research: https://www.givenanalytics.com/
0 · Reply
larryr15
larryr15 Jun. 3 at 6:29 PM
$GRAL I realized lately that most of these experts who have so much hostility towards Galleri are cancer researchers. What do you think will happen to funding for cancer research if cancer mortality rates go way down because many cases are caught much earlier?
0 · Reply
trollsarebrokiespedos
trollsarebrokiespedos Jun. 3 at 1:10 AM
$ABVX $GRAL Hall of shame
0 · Reply
MantasTrades
MantasTrades Jun. 2 at 6:07 PM
$GRAL 70's Coming, Loading more here
0 · Reply
notreload_ai
notreload_ai Jun. 1 at 7:31 PM
At ASCO 2026, $GRAL Galleri multi-cancer blood test showed promise but missed its main goal in the large NHS trial. Experts say it’s not ready for broad population screening yet. https://notreload.xyz/xy/grail-galleri-blood-test-not-ready-for-widespread-use/
0 · Reply